Latest News
BioCryst Pharmaceuticals, Inc.
- BioCryst Pharmaceuticals, Inc. Estimates – TRADEGATE:BO1
- FDA Clears Oral Pellets That Could Be A Game Changer For BioCryst Pharmaceuticals (BCRX)
- BioCryst Pharmaceuticals Q3FY26 Results: Earnings call set for Nov 4
- BioCryst to Report Third Quarter 2026 Financial Results on November 4
- BioCryst Pharmaceuticals (BCRX) Gains FDA Nod for New Orladeyo O
- BioCryst wins FDA nod for Orladeyo oral pellets (BCRX:NASDAQ)
- BioCryst Pharmaceuticals wins FDA approval for 150 mg ORLADEYO pellets
- BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
- How New Advisory Board At BioCryst Pharmaceuticals (BCRX) Has Changed Its Investment Story
- People on the Move: BioCryst Forms Scientific Advisory Board of Seven Rare Disease Leaders
- BioCryst Pharmaceuticals (BCRX) Names Scientific Advisory Board, Is The Discount Too Wide?
- BioCryst Forms Scientific Advisory Board to Guide Rare Disease Pipeline
Headlines from the last 30 days, linking to the original publishers. See all market news →